Background This study focused on minimizing the costs and toxic effects associated with
unnecessary chemotherapy. We sought to optimize the adjuvant therapy strategy, choosing …

Background There is a lack of individualized evidence on surgical choices for glioblastoma
(GBM) patients. Aim This study aimed to make individualized treatment recommendations for …

Background The aim was to predict survival of glioblastoma at 8 months after radiotherapy
(a period allowing for completing a typical course of adjuvant temozolomide), by applying …

This study aimed to investigate the performance of a deep learning-based survival-
prediction model, which predicts the overall survival (OS) time of glioblastoma patients who …

Background Glioblastoma (GBM) is the most common brain tumor in the United States, with
an annual incidence rate of 3.21 per 100,000. It is the most aggressive type of diffuse glioma …

Purpose Precision medicine has been most successful in targeting single mutations, but
personalized medicine using broader genomic tumor profiles for individual patients is less …

OBJECTIVE Contemporary oncological paradigms for adjuvant treatment of low-and
intermediate-grade gliomas are often guided by a limited array of parameters, overlooking …

Methods We randomly selected 10 patients with brain gliomas discussed at our institution's
central nervous system tumour board (CNS TB). Patients' clinical status, surgical outcome …

Background Glioblastoma (GBM) is the most common malignant brain tumor in adults. The
prognosis of GBM patients is poor. Even with active standard treatment, the median overall …

Standard treatment for glioblastoma multiforme (GBM) is surgery followed by radiotherapy
plus concurrent chemotherapy with daily temozolomide (TMZ), and six subsequent TMZ 5/28 …